Abstract
In Sri Lanka, the usual treatment for severe local envenomation by the hump-nosed viper (Hypnale hypnale) is with polyspecific snake antivenom. We carried out a prospective, randomized, placebo-controlled, single-blind clinical trial to determine the efficacy and safety of polyspecific snake antivenom in the treatment of severe local envenomation by this snake. Sixty-three patients with signs and symptoms of local envenomation by the hump-nosed viper Lanka were randomized to receive either polyspecific snake antivenom or normal saline. The two groups were similar in age, sex, time of presentation to hospital, and degree of envenomation. There was no significant difference between the antivenom and placebo groups in the time taken for complete resolution of the local envenomation (5.52 days versus 4.77 days; P = 0.53, by the Mann-Whitney U test). There was a 44.82% incidence of adverse reactions associated with treatment with antivenom. We conclude that polyspecific snake antivenom is not indicated for severe local envenomation by the hump-nosed viper.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The American Journal of Tropical Medicine and Hygiene
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
